LDLR and Hypercholesterolemia: Moreover, proprotein convertase subtilisin/kexin type-2 (PCSK9) inhibitors, potent agents against hypercholesterolemia, might enhance the expression of hepatic low-density lipoprotein receptors and accelerate FVIII degradation within the liver, thereby lowering circulating FVIII levels [119].